Cargando…

NP-MRD: the Natural Products Magnetic Resonance Database

The Natural Products Magnetic Resonance Database (NP-MRD) is a comprehensive, freely available electronic resource for the deposition, distribution, searching and retrieval of nuclear magnetic resonance (NMR) data on natural products, metabolites and other biologically derived chemicals. NMR spectro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wishart, David S, Sayeeda, Zinat, Budinski, Zachary, Guo, AnChi, Lee, Brian L, Berjanskii, Mark, Rout, Manoj, Peters, Harrison, Dizon, Raynard, Mah, Robert, Torres-Calzada, Claudia, Hiebert-Giesbrecht, Mickel, Varshavi, Dorna, Varshavi, Dorsa, Oler, Eponine, Allen, Dana, Cao, Xuan, Gautam, Vasuk, Maras, Andrew, Poynton, Ella F, Tavangar, Pegah, Yang, Vera, van Santen, Jeffrey A, Ghosh, Rajarshi, Sarma, Saurav, Knutson, Eleanor, Sullivan, Victoria, Jystad, Amy M, Renslow, Ryan, Sumner, Lloyd W, Linington, Roger G, Cort, John R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Database Issue
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728158/ https://www.ncbi.nlm.nih.gov/pubmed/34791429 http://dx.doi.org/10.1093/nar/gkab1052

Ejemplares similares

HMDB 5.0: the Human Metabolome Database for 2022
por: Wishart, David S, et al.
Publicado: (2021)

Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines
por: Varshavi, Dorna, et al.
Publicado: (2020)

Metabonomics study of the effects of single copy mutant KRAS in the presence or absence of WT allele using human HCT116 isogenic cell lines
por: Varshavi, Dorna, et al.
Publicado: (2021)

MarkerDB: an online database of molecular biomarkers
por: Wishart, David S, et al.
Publicado: (2020)

Treatment of wild-type mice with 2,3-butanediol, a urinary biomarker of Fmo5 (−/−) mice, decreases plasma cholesterol and epididymal fat deposition
por: Veeravalli, Sunil, et al.
Publicado: (2022)

Metabolic Biomarkers of Ageing in C57BL/6J Wild-Type and Flavin-Containing Monooxygenase 5 (FMO5)-Knockout Mice
por: Varshavi, Dorsa, et al.
Publicado: (2018)

ChemFOnt: the chemical functional ontology resource
por: Wishart, David S, et al.
Publicado: (2022)

MiMeDB: the Human Microbial Metabolome Database
por: Wishart, David S, et al.
Publicado: (2022)

CFM-ID 4.0 – a web server for accurate MS-based metabolite identification
por: Wang, Fei, et al.
Publicado: (2022)

PHASTEST: faster than PHASTER, better than PHAST
por: Wishart, David S, et al.
Publicado: (2023)

A guide to the identification of metabolites in NMR-based metabonomics/metabolomics experiments
por: Dona, Anthony C., et al.
Publicado: (2016)

BioTransformer 3.0—a web server for accurately predicting metabolic transformation products
por: Wishart, David S, et al.
Publicado: (2022)

PlasMapper 3.0—a web server for generating, editing, annotating and visualizing publication quality plasmid maps
por: Wishart, David S, et al.
Publicado: (2023)

411 Mrd. €, 11,9 %
por: Kuhn, Joseph
Publicado: (2022)

The phenotype of a knockout mouse identifies flavin-containing monooxygenase 5 (FMO5) as a regulator of metabolic ageing
por: Gonzalez Malagon, Sandra G., et al.
Publicado: (2015)

MRD in AML: The Role of New Techniques
por: Voso, Maria Teresa, et al.
Publicado: (2019)

HOW TO INCORPORATE MRD IN CLINICAL TRIALS
por: San-Miguel, Jesus
Publicado: (2022)

NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol
por: Svaton, Michael, et al.
Publicado: (2023)

PathBank: a comprehensive pathway database for model organisms
por: Wishart, David S, et al.
Publicado: (2020)

Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all
por: Kuiper, Roland P., et al.
Publicado: (2021)

Mutations in cell elongation genes mreB, mrdA and mrdB suppress the shape defect of RodZ-deficient cells
por: Shiomi, Daisuke, et al.
Publicado: (2013)

MRD in multiple myeloma: more questions than answers?
por: Moreau, Philippe, et al.
Publicado: (2017)

SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia?
por: Turcas, Cristina, et al.
Publicado: (2020)

MRD negativity: considerations for older adults with multiple myeloma
por: Mian, Hira, et al.
Publicado: (2023)

P889: WILL OUTCOME IMPROVE BY TREATING MULTIPLE MYELOMA PATIENTS AT MRD RELAPSE? THE REMNANT STUDY (RELAPSE FROM MRD NEGATIVITY AS INDICATION FOR TREATMENT)
por: Askeland, F. B., et al.
Publicado: (2022)

Mandibular Repositioning Device (MRD) and Obstructive Sleep Apnea Syndrome
por: Nicolaou, Zoe
Publicado: (2019)

MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
por: Bernardi, Massimo, et al.
Publicado: (2022)

Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma
por: Coffey, David G., et al.
Publicado: (2023)

1661. Using Social Media to Enhance an STI Screening Program in Wuhan, China
por: Newman McCort, Margaret E, et al.
Publicado: (2019)

Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study)
por: Nagafuji, Koji, et al.
Publicado: (2013)

A Cost Impact Analysis of clonoSEQ(®) as a Valid and CE-Certified Minimal Residual Disease (MRD) Diagnostic Compared to No MRD Testing in Multiple Myeloma in Germany
por: Walzer, Stefan, et al.
Publicado: (2021)

Role of peripheral blood MRD and 18F-FDG PET in the post-CAR relapse setting: a case study of discordant peripheral blood and bone marrow MRD
por: Schultz, Liora, et al.
Publicado: (2023)

getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)

Analysis of Subset Chimerism for MRD-Detection and Pre-Emptive Treatment in AML
por: Georgi, Julia-Annabell, et al.
Publicado: (2022)

The Utility of Euroflow MRD Assessment in Real-World Multiple Myeloma Practice
por: Turner, Rose, et al.
Publicado: (2022)

Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?
por: Guolo, Fabio, et al.
Publicado: (2022)

Utility of flow cytometry screening before MRD testing in multiple myeloma
por: Panakkal, Vandana, et al.
Publicado: (2023)

Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
por: Maiolino, Angelo, et al.
Publicado: (2023)

P1402: INFUSION OF 14 DAYS BLINATUNOMAB IN COMBINATION WITH CHEMOTHERAPY FOR 46-DAY MRD+ PEDIATRIC B-ALL PATIENTS IN INTERMEDIATE/HIGH-RISK GROUP RESULTS IN MRD CONVERSION.
por: Xue, Changwen, et al.
Publicado: (2023)

Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment
por: Kriegsmann, Katharina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_74ic89n7prj388hsj7kqclktme